
CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 32765-32965
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T223","span":{"begin":0,"end":200},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gene expression microarrays (Affymetrix Human Genome U133 Plus 2.0) were performed in peripheral blood mononuclear cells from 8 MS patients at baseline and after 3, 12 and 24 months of IFNb treatment."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T223","span":{"begin":0,"end":200},"obj":"Sentence"}],"text":"Gene expression microarrays (Affymetrix Human Genome U133 Plus 2.0) were performed in peripheral blood mononuclear cells from 8 MS patients at baseline and after 3, 12 and 24 months of IFNb treatment."}
CORD-19-PD-UBERON
{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T130","span":{"begin":97,"end":102},"obj":"Body_part"},{"id":"T131","span":{"begin":128,"end":130},"obj":"Body_part"}],"attributes":[{"id":"A130","pred":"uberon_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A131","pred":"uberon_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"Gene expression microarrays (Affymetrix Human Genome U133 Plus 2.0) were performed in peripheral blood mononuclear cells from 8 MS patients at baseline and after 3, 12 and 24 months of IFNb treatment."}
CORD-19-PD-MONDO
{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T155","span":{"begin":128,"end":130},"obj":"Disease"},{"id":"T57660","span":{"begin":128,"end":130},"obj":"Disease"}],"attributes":[{"id":"A94749","pred":"mondo_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A61148","pred":"mondo_id","subj":"T57660","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"Gene expression microarrays (Affymetrix Human Genome U133 Plus 2.0) were performed in peripheral blood mononuclear cells from 8 MS patients at baseline and after 3, 12 and 24 months of IFNb treatment."}